CompletedNot Applicable

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

Japan366 participantsStarted 2023-01-06

Plain-language summary

To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For treatment of symptomatic disease caused by SARS-CoV-2 infection; Patients with risk factors for severe SARS-CoV-2 infection who do not require supplemental oxygen. * For prevention of symptomatic disease caused by SARS-CoV-2 infection; Individuals for whom SARS-CoV-2 vaccination is not recommended OR those who are considered to have an inadequate response to a COVID-19 vaccine due to immunodeficiencies AND who is not close contacts such as family members or other people living in the same dwelling as patients infected with SARS-CoV-2. Exclusion Criteria: * None

What they're measuring

Incidence of ADRs

Timeframe: 24weeks(6 months)

Trial details

NCT IDNCT05687877

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-01-20

View on ClinicalTrials.gov More SARS-CoV-2 Infection trials